HLA-A∗11:01-restricted CD8 T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people

JR Habel; AT Nguyen; LC Rowntree; C Szeto; NA Mifsud; EB Clemens; L Loh; W Chen; S Rockman; J Nelson; J Davies; A Miller; SYC Tong; J Rossjohn; S Gras; AW Purcell; L Hensen; K Kedzierska; PT Illing

Journal article

HLA-A∗11:01-restricted CD8 T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people

JR Habel, AT Nguyen, LC Rowntree, C Szeto, NA Mifsud, EB Clemens, L Loh, W Chen, S Rockman, J Nelson, J Davies, A Miller, SYC Tong, J Rossjohn, S Gras, AW Purcell, L Hensen, K Kedzierska, PT Illing

Plos Pathogens | Published : 2022

DOI: 10.1371/journal.ppat.1010337

Download PDF

Abstract

HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide broadly cross-reactive immunity to distinct influenza strains and subtypes, including influenza A, B and C viruses, understanding CD8+ T cell immunity to influenza viruses across prominent HLA types is needed to rationally design a universal influenza vaccine and generate protective immunity especially for high-risk populations. As only a handful of HLA-A*11:01-restricted CD8+ T cell epitopes have been described for influenza A viruses (IAVs) a..

View full abstract

University of Melbourne Researchers

Jennifer Habel Author

Louise Rowntree Author

Bridie Clemens Author

Liyen Loh Author

Related Projects (2)

LIMITING THE IMPACT OF INFLUENZA

The development of better ways to prevent and treat influenza infection will be a major step forward in lessening the impact of the virus in..

GENERATION OF PROTECTIVE IMMUNITY AGAINST SEVERE INFLUENZA DISEASE IN INDIGENOUS AUSTRALIANS

Hospitalisation and death rates from influenza are high in the Indigenous population, especially when a new virus emerges. There is an urgen..

Grants

Awarded by Australian Cancer Research Foundation

Funding Acknowledgements

This study was supported by the Australian National Health and Medical Research Council(NHMRC) Program Grant(#1071916) to K.K., NHMRC Project Grant(#1122524)to K.K., S.Y.C.T., A.M.,S.G. and A.W.P.,NHMRC Investigator Grant(#1173871) to K.K., the Research Grants Council of the Hong Kong Special Administrative Region,China(#T11-712/19-N) to K.K, NHMRC Project grant(#1085018)to A.W.P. and N.A.M. Salary support: K.K. was supported by the NHMRC Investigator Fellowship(#1173871), J.R. by an ARC Laureate fellowship(FL160100049),S.G. by an NHMRC SRF-A Fellow(#1159272), A.W.P.by an NHMRC Principal Research Fellowship(#1137739)and S.Y.C.T.is an NHMRC Career Development Fellow(#1145033).E.B.C. was supported by an NHMRC Peter Doherty Fellowship(#1091516), A.T.N.is supported by a Monash BDI PhD scholarship and an AINSE Ltd. Postgraduate Research Award (PGRA), J.R.H.was supported by the Melbourne Research Scholarship, L.H. was a recipient of Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship. The funders had no role in study design,data collection and analysis, decision to publish, or preparation of the manuscript.